View in browser

November 4, 2024

New Spatial Omics Technologies Available from Moores Genomics and Computational Biology Shared Resource (GCBSR)

Among ongoing efforts to support your research, Moores would like to bring to your attention new services that are available through GCBSR, through its collaboration with the IGM Genomics Center. Several workflows for spatial omics platforms are now available for Moores Members. Cost estimates are provided below for general research planning; actual costs can be determined in discussion with GCBSR.

10X Genomics Visium with Cytassist

High-throughput spatial transcriptomics with a full-transcriptome NGS readout
Slide Area: 6.5 mm x 6.5 mm
Pricing: ≈ $3,500 per 6.5 mm x 6.5 mm area

Learn more about Visium

 

10X Genomics Xenium

Uses high-resolution imaging technology; choose from a variety of panels, including the latest 5,000 gene panel; custom panels and add-ons available
Slide Area: 10 mm x 22 mm
Pricing: Starting at $4,200 per 10 mm x 22 mm

Discover Xenium

 

Nanostring GeoMX Digital Spatial Profiler

GeoMx DSP allows for selecting regions of interest and maintenance of spatial context during high-resolution, high-throughput analysis to elucidate spatial heterogeneity within tissue samples at the molecular level
Slide Area: 36 mm x 14 mm (0.25 cm²)
Pricing: From ≈ $4,000

Explore GeoMX

 

Possibly Coming Soon: NanoString CosMx

If you are interested in this innovative technology, then please contact GCBSR for more information.

 

For inquiries or to schedule a consultation, please contact GCBSR Director Kristen Jepsen, PhD at kjepsen@health.ucsd.edu.

 

For more GCBSR information, join the IGM mailing list: https://mailman.ucsd.edu/mailman/listinfo/igmgenomicscenter-l 

 

In addition, analysis services are available through the Center for Computational Biology and Bioinformatics (CCBB). For more information, please visit CCBB's Services Page or contact CCBB Director Brin Rosenthal, PhD at sbrosenthal@health.ucsd.edu.

FEATURED FUNDING OPPORTUNITIES

 

The Metastasis Research Network (MetNet): MetNet Research Projects (U01 Clinical Trial Not Allowed)

LOI Deadline: May 20, 2025

Application Deadline: June 20, 2025

Budget: $500,000 per year for 5 years

SEE ALL FUNDING OPPORTUNITIES

RESEARCHER SPOTLIGHT

 

The Researcher Spotlight is designed to help you connect with fellow researchers, gain insights into their diverse projects, and discover the paths that led them to their current roles. Uncover a personal touch to their professional achievements, showcasing the varied perspectives within our cancer research community.

ratio 

LUDMIL B. ALEXANDROV, PHD

Dr. Ludmil Alexandrov is a Professor at the Department of Cellular and Molecular Medicine and the Department of Bioengineering at the University of California San Diego. Dr. Alexandrov’s research focuses on understanding the information hidden in large-scale omics datasets. He is particularly interested in elucidating the mechanisms by which cancers develop and in leveraging this knowledge for the development of better cancer prevention strategies and the improved targeting of existing cancer treatment.

WATCH VIDEO

RECENT PUBLICATIONS

 

Low PD-L1 expression, MAP2K2 alterations, and enriched HPV gene signatures characterize brain metastases in head and neck squamous cell carcinoma

Journal of Translational Medicine

Ida Deichaite, PhD (Structural and Functional Genomics), Michael J. Dennis, MD (Solid Tumor Therapeutics), and David Piccioni, MD, PhD (Solid Tumor Therapeutics)

Efficacy of adding veliparib to temozolomide for patients with MGMT-methylated glioblastoma: A randomized clinical trial

JAMA Oncology

David Piccioni, MD, PhD (Solid Tumor Therapeutics)

Perioperative tislelizumab plus intensity modulated radiotherapy in resectable hepatocellular carcinoma with macrovascular invasion: A phase II trial

Nature Communications

Jin Zhang, PhD (Cancer Biology and Signaling)

CLINICAL TRIALS OFFICE (CTO)

 

CLINICAL TRIALS

GOG3068/HOTT: A Phase III Randomized Trial of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Cisplatin Versus No HIPEC at the Time of Optimal Interval Cytoreductive Surgery Followed by Niraparib Maintenance in Patients with Newly Diagnosed Stage III and IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer (Heated Ovarian Treatment Trial)

PI: Michael McHale, MD

NCT: NCT05659381

CLINICAL TRIALS

 
  • Senior Scientist - 131183
  • Gleiberman Program Administrator - 132565

Subscribe

About Us

Contact Us

Alternate Text logo

Department of Research Administration

3855 Health Sciences Drive, La Jolla, CA 92037

moorescancercenter.ucsd.edu

 

Unsubscribe | Privacy Policy | Submit Feedback